Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2021 | NSCLC | Research article

Polysaccharides from Ganoderma Sinense - rice bran fermentation products and their anti-tumor activities on non-small-cell lung cancer

Authors: Wei Han, Hongjuan Chen, Lin Zhou, Haijie Zou, Xiaohong Luo, Bo Sun, Xuhui Zhuang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

Non-small-cell lung cancer (NSCLC) accounts more than 80% of the lung cancer cases. Polysaccharides in rice bran and its fermentation products have been proven to suppress many cancers. However, the report on inhibiting NSCLC is few. In this paper, the polysaccharides with suppression activity to H1299 NSCLC in the fermentation products of full-fat rice bran and defatted rice bran were studied in vitro and in vivo.

Method

Polysaccharides (GSRBPs) were extracted from Ganoderma sinense – full-fat rice bran (GS-FRB) and Ganoderma sinense – defatted rice bran (GS-DRB) fermentation products. The structure information of the GSRBPs was studied using HPLC analysis. The anti-tumor activities on H1299 NSCLC of GSRBPs in vitro study was performed using MTT method. The in vivo studies use BALB/c-nu nude mice as H1299 NSCLC bearing mice.

Result

All the polysaccharides contained two fractions, GSFPS-1 and GSFPS-2. The molecular weight and the ratio of GSFPS-1 and GSFPS-2 were different in GS-FRB and GS-DRB. At the earlier state of fermentation, all polysaccharides were composed of D-glu, D-man, D-xyl and L-ara with certain molar ratios. But at the latter stage, polysaccharides in GS-FRB were composed of D-glu, D-man, D-xyl, L-ara and D-fru, while these in GS-DRB only composed of D-glu and D-man. In the in vitro study, the IC50 of RBS and GSRBPs was as GS-DRB-11 (40.62 μg/mL), GS-FRB-9 (43.82 μg/mL), GS-DRB-7 (48.08 μg/mL), RBS (49.56 μg/mL), GS-DRB-9 (49.91 μg/mL), GS-DRB-13 (51.89 μg/mL), GS-FRB-11 (53.75 μg/mL), GS-FRB-7 (56.84 μg/mL), GS-DRB-13 (60.63 μg/mL) from small to large. In the in vivo study, the H1299 NSCLC inhibition rate (InRa) of RBS and GSRBPs were GS-DRB-11 (86.81%) > GS-DRB-9 (86.01%) > GS-FRB-9 (84.88%) > GS-DRB-7 (82.21%) > GS-DRB-13 (78.04%) > RBS (76.06%) > GS-FRB-13 (65.44%) > GS-FRB-11 (64.70%) > GS-FRB-7 (27.87%). The GSFPS-2 area percent was negatively correlated to the IC50 and was positively correlated to the InRa. This means the GSFPS-2 had much higher anti-tumor activity than GSFPS-1.

Conclusion

GSFPS-2 had higher anti-tumor activities, and the lipid in the rice bran has a decisive effect on the structures of polysaccharides produced by fermentation. Therefore, GSRBPs could be considered as potential novel agents to suppress H1299 non-small-cell lung cancer.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;60:235–44.

Naveed R, Humera K. The evolving role of histology in the treatment of non-small cell lung cancer. Med Health. 2010;93:317–9.

Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006;11(3):274–84. https://doi.org/10.1634/theoncologist.11-3-274.CrossRefPubMed

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung Cancer. New Engl J Med. 2002;346(2):92–8. https://doi.org/10.1056/NEJMoa011954.CrossRefPubMed

Guo W, Liu S, Ju X, Du J, Xu B, Yuan H, et al. The antitumor effect of hinesol, extract from Atractylodes lancea (Thunb.) DC. By proliferation, inhibition, and apoptosis induction via MEK/ERK and NF-κB pathway in non–small cell lung cancer cell lines A549 and NCI-H1299. J Cell Biochem. 2019;120(11):18600–7. https://doi.org/10.1002/jcb.28696.CrossRefPubMed

Zhou Y, Hong T, Tong L, Liu W, Yang X, Luo J, et al. Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP 4K3/mTOR signaling pathway. Int J Mol Med. 2018;42(6):3093–104. https://doi.org/10.3892/ijmm.2018.3868.CrossRefPubMedPubMedCentral

Liu X-C, Zhu Z-Y, Liu Y-L, Sun H-Q. Comparisons of the anti-tumor activity of polysaccharides from fermented mycelia and cultivated fruiting bodies of Cordyceps militaris in vitro. Int J Biol Macromol. 2019;130:307–14. https://doi.org/10.1016/j.ijbiomac.2019.02.155.CrossRefPubMed

Liu K, Gao W, Lin J. Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line. Oncol Lett. 2017;14(2):1411–8. https://doi.org/10.3892/ol.2017.6356.CrossRefPubMedPubMedCentral

Yang S-Y, Li Y, An G-S, Ni J-H, Jia H-T, Li S-Y. DNA Damage-Response Pathway Heterogeneity of Human Lung Cancer A549 and H1299 Cells Determines Sensitivity to 8-Chloro-Adenosine. Int J Mol Sci. 2018;19(1587):1515.

10.

Moure A, Cruz JM, Franco D, Domínguez JM, Sineiro J, Domínguez H, et al. Natural antioxidants from residual sources. Food Chem. 2001;72(2):145–71. https://doi.org/10.1016/S0308-8146(00)00223-5.CrossRef

11.

Takeshita M, Nakamura S, Makita F, Ohwada S, Miyamoto Y, Morishita Y. Antitumor effect of RBS (rice bran saccharide) on ENNG-induced carcinogenesis. Biother. 1992;4(2):139–45. https://doi.org/10.1007/BF02171758.CrossRef

12.

Wang L, Huang H, Wei Y, Li X, Chen Z. Characterization and anti-tumor activities of sulfated polysaccharide SRBPS2a obtained from defatted rice bran. Int J Biol Macromol. 2009;45(4):427–31. https://doi.org/10.1016/j.ijbiomac.2009.06.006.CrossRefPubMed

13.

Takeo S, Kado H, Yamamoto H, Kamimura M, Watanabe N, Uchida K, et al. Studies on an antitumor polysaccharide RBS derived from rice bran. II. Preparation and general properties of RON, an active fraction of RBS. Chem Pharm Bull. 1988;36(9):3609–13. https://doi.org/10.1248/cpb.36.3609.CrossRef

14.

Ooi SL, McMullen D, Golombick T, Nut D, Pak SC. Evidence-based review of BioBran/MGN-3 Arabinoxylan compound as a complementary therapy for conventional Cancer treatment. Integr Cancer Ther. 2018;17(2):165–78. https://doi.org/10.1177/1534735417735379.CrossRefPubMed

15.

Jiang Y, Chang Y, Liu Y, Zhang M, Luo H, Hao C, et al. Overview of Ganoderma sinense polysaccharide–an adjunctive drug used during concurrent chemo/radiation therapy for cancer treatment in China. Biomed Pharmacother. 2017;96:865–70. https://doi.org/10.1016/j.biopha.2017.09.060.CrossRefPubMed

16.

Hioki K, Kuramochi T, Endoh S, Terada E, Ueyama Y, Ito M. Lack of B cell leakiness in BALB/cA-nu, scid double mutant mice. Exp Anim. 2001;50(1):67–72. https://doi.org/10.1538/expanim.50.67.CrossRefPubMed

17.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. https://doi.org/10.1126/science.1160809.CrossRefPubMedPubMedCentral

18.

Fan TWM, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8(1):41. https://doi.org/10.1186/1476-4598-8-41.CrossRefPubMedPubMedCentral

19.

Tsun Z-Y, Possemato R. Amino acid management in cancer. Semin Cell Dev Biol. 2015;43:22–32. https://doi.org/10.1016/j.semcdb.2015.08.002.CrossRefPubMedPubMedCentral

20.

Liu Q, Cao X, Zhuang X, Han W, Guo W, Xiong J, et al. Rice bran polysaccharides and oligosaccharides modified by Grifola frondosa fermentation: antioxidant activities and effects on the production of NO. Food Chem. 2017;223:49–53. https://doi.org/10.1016/j.foodchem.2016.12.018.CrossRefPubMed

21.

Liu S, Zhuang X, Zhang X, Han W, Liu Y, Sun D, et al. Enzymatic modification of Rice bran polysaccharides by enzymes from Grifola Frondosa: natural killer cell cytotoxicity and antioxidant activity. J Food Sci. 2018;83(7):1948–55. https://doi.org/10.1111/1750-3841.14148.CrossRefPubMed

22.

Tanigami Y, Kusumoto S, Nagao S, Kokeguchi S, Kato K, Kotani S, et al. Partial degradation and biological activities of an antitumor Polysaccharide from Rice bran. Chem Pharm Bull. 1991;39(7):1782–7. https://doi.org/10.1248/cpb.39.1782.CrossRef

23.

El-Din NKB, Noaman E, Ghoneum M. In vivo tumor inhibitory effects of nutritional Rice bran supplement MGN-3/Biobran on Ehrlich carcinoma-bearing mice. Nutr Cancer. 2008;60(2):235–44. https://doi.org/10.1080/01635580701627285.CrossRef

Title: Polysaccharides from Ganoderma Sinense - rice bran fermentation products and their anti-tumor activities on non-small-cell lung cancer
Authors: Wei Han
Hongjuan Chen
Lin Zhou
Haijie Zou
Xiaohong Luo
Bo Sun
Xuhui Zhuang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03346-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Polysaccharides from Ganoderma Sinense - rice bran fermentation products and their anti-tumor activities on non-small-cell lung cancer

Abstract

Background

Method

Result

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Traditional and complementary medicine use among chronic haemodialysis patients: a nationwide cross-sectional study

The trends of complementary alternative medicine use among cancer patients

Antidiarrheal, antimicrobial and antioxidant potentials of methanol extract of Colocasia gigantea Hook. f. leaves: evidenced from in vivo and in vitro studies along with computer-aided approaches

Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat

Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial

Evaluation of antinociceptive activity of Ilex dipyrena Wall. in mice